SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Aethlon Medical Inc.

Armistice Capital, LLC and Steven Boyd have jointly reported a beneficial ownership of 9.99% in Aethlon Medical Inc.'s common stock as of March 31, 2025.

Summary

• The filing identifies Armistice Capital, LLC and Steven Boyd as the Reporting Persons.
• The issuer is AETHLON MEDICAL INC, with its principal executive offices located at 11555 Sorrento Valley Road, Suite 203, San Diego, CA, 92121.
• The securities in question are Common Stock, $0.001 par value, with CUSIP Number 00808Y406.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 1,446,074 shares of Aethlon Medical Inc.'s common stock.
• This ownership represents 9.99% of the class of securities.
• The Reporting Persons hold shared voting power and shared dispositive power over all 1,446,074 shares.
• Armistice Capital, LLC is the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own these securities.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant institutional investment, which is generally a positive signal of confidence in the company. However, it provides no operational or financial details about the company itself, limiting a comprehensive sentiment assessment.

Positives

• A significant institutional investor, Armistice Capital, LLC, has disclosed a substantial 9.99% stake in Aethlon Medical Inc., which can be interpreted as a vote of confidence in the company's prospects.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive investment intent.

Negatives

• The document, being a beneficial ownership report (Schedule 13G), does not contain any negative financial or operational information about Aethlon Medical Inc.

Risks

• The document itself does not detail specific risks related to Aethlon Medical Inc.'s operations or financial health, as it is a Schedule 13G filing focused solely on ownership disclosure.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant passive investment by Armistice Capital, LLC and Steven Boyd in Aethlon Medical Inc. Such filings are common in the investment landscape, reflecting institutional interest in publicly traded companies. While the document does not provide specific industry details for Aethlon Medical Inc., a nearly 10% stake by an investment firm can be seen as a vote of confidence within its respective sector, potentially signaling perceived value or growth opportunities.

Stakeholder Impact

• Shareholders may view the disclosure of a significant stake by Armistice Capital as a positive indicator of institutional confidence, which could potentially influence investor sentiment and the company's stock price.

Key Dates

Keywords

Aethlon Medical Inc., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Healthcare, Biotechnology